Industry Pulse
Regulatory
FDA actions, compounding policy and enforcement developments, and what each one means for research peptide supply.
Ten Weeks After the Advisory Vote, FDA Peptide Compounding Decision Remains Pending
Ten weeks after the PCAC recommended six peptides for the 503A Bulks List, the FDA has not acted. States are splitting, enforcement continues, and verification matters more than ever.
Read Analysis →
FDA Panel Recommends Six of Seven Peptides for Compounding, Rejects Emideltide
FDA Panel Recommends Six of Seven Peptides for Compounding, Rejects EmideltideThe FDA’s Pharmacy Compounding Advisory Committee closed its two-day meeting on July 24 having recommended six of the seven peptides under review for the Section 503A Bulk Drug Substances List. Only emideltide, also known as…
Read Analysis →
FDA Warns San Diego Pharmacist Over Unapproved Retatrutide and Tirzepatide Sales
FDA Warns San Diego Pharmacist Over Unapproved Retatrutide and Tirzepatide SalesBernard Gramlich, founder of GRAM peptides and a former Rancho Santa Fe pharmacist, has agreed to stop selling retatrutide and tirzepatide injections online after receiving a formal warning letter from the FDA in March, according…
Read Analysis →
RFK, the FDA, and Seven Peptides: What to Expect from the July 2026 PCAC Review
RFK, the FDA, and Seven Peptides: What to Expect from the July 2026 PCAC ReviewIndustry Pulse › RFK and the FDA July 2026 Peptide Decision May 24, 2026 · Regulatory Research Use Only. This article analyzes upcoming FDA regulatory activity in the context of research…
Read Analysis →
The FDA Peptide Reclassification of 2026: What Actually Changed, What’s Pending, and What It Means for Research Suppliers
The FDA Peptide Reclassification of 2026: What Actually Changed, What’s Pending, and What It Means for Research SuppliersIndustry Pulse › The FDA Peptide Reclassification of 2026 May 23, 2026 · Regulatory In the first half of 2026, the FDA built and deployed a framework. The…
Read Analysis →
FDA Reverses Course on Seven Peptides: PCAC Reviews BPC-157, TB-500, KPV in July
The FDA Pharmacy Compounding Advisory Committee will convene July 23-24, 2026 to consider adding BPC-157, TB-500, KPV, Semax, Epitalon and others to the 503A bulks list. If recommended, compounding pharmacies could legally prepare these compounds for the first time.
Read Analysis →
FDA Moves to Ban Compounded Semaglutide and Tirzepatide: What Researchers Need to Know
FDA Moves to Ban Compounded Semaglutide and Tirzepatide: What Researchers Need to KnowIndustry Pulse › FDA Moves to Ban Compounded Semaglutide and Tirzepatide May 1, 2026 · Regulatory On May 1, 2026, the FDA filed a proposal that would effectively end large-scale compounding of semaglutide,…
Read Analysis →Research Use Only. Industry Pulse coverage is provided for research and educational reference only and does not constitute legal or medical advice. GENEVIUM products are not for human or animal consumption.